Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Scripps Korea Antibody Institute maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the institute has 1 pending office action, which is being reviewed by 1 distinct examiner. This indicates a highly specific and narrow focus for the institute's current active patent applications. The presence of 1 distinct art unit further confirms that these efforts are concentrated within a single specialized technical group at the patent office, rather than being distributed across multiple units.
The busiest examiner identified is JADHAO, SAMADHAN JAISING, who is currently managing 1 busiest examiner pending office action. Since the total number of pending office actions for the institute is 1, this examiner is handling all of the institute's current prosecution activity. This one-to-one ratio between the pending action and the examiner suggests a very straightforward prosecution environment. The institute's immediate progress in the Biotechnology & Pharmaceuticals sector is currently dependent on the review and decisions of this single examiner, with no other active matters in the pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259018 | SARS-CORONAVIRUS 2 NEUTRALIZING ANTIBODY | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259018 | SARS-CORONAVIRUS 2 NEUTRALIZING ANTIBODY | JADHAO, SAMADHAN JAISING | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259018 | SARS-CORONAVIRUS 2 NEUTRALIZING ANTIBODY | JADHAO, SAMADHAN JAISING | 1672 | §101§103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial